Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study
|
|
- Colin Paul
- 5 years ago
- Views:
Transcription
1 Accepted Manuscript Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study Danny R. Youlden, Peter D. Baade, H Peter Soyer, Philippa H. Youl, Michael G. Kimlin, Joanne F. Aitken, Adele C. Green, Kiarash Khosrotehrani PII: DOI: Reference: JID 264 S X(16) /j.jid To appear in: The Journal of Investigative Dermatology Received Date: 21 January 2016 Revised Date: 23 February 2016 Accepted Date: 9 March 2016 Please cite this article as: Youlden DR, Baade PD, Soyer HP, Youl PH, Kimlin MG, Aitken JF, Green AC, Khosrotehrani K, Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study, The Journal of Investigative Dermatology (2016), doi: / j.jid This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
2 Title: Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study Short title: Multiple invasive melanoma survival Authors: Danny R Youlden 1, Peter D Baade 1-3, H Peter Soyer 4,5, Philippa H Youl 1-3, Michael G Kimlin 1,6, Joanne F Aitken 1,2, Adele C Green 7,8, Kiarash Khosrotehrani 5,9,10 1 Cancer Council Queensland, Brisbane, Queensland, Australia. 2 School of Public Health and Social Work, Queensland University of Technology, Brisbane, Queensland, Australia. 3 Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia. 4 Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia 5 Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 6 Health Research Institute, University of the Sunshine Coast, Sunshine Coast, Queensland, Australia. 7 QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 8 CRUK Manchester Institute and Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom. 9 The University of Queensland, UQ Centre for Clinical Research, Brisbane, Queensland, Australia. 10 The University of Queensland, UQ Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia. Corresponding author: A/Prof Kiarash Khosrotehrani, The University of Queensland Diamantina Institute, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia, Tel.: , Fax: , k.khosrotehrani@uq.edu.au. Word count: Main text: 3,363 words Abstract: 197 words Tables: 3 Figures: 2 Abbreviations: HR = hazard ratio; CI = confidence interval. 1 P a g e
3 Abstract The prognosis of melanoma patients who are diagnosed with multiple primary lesions remains controversial. We used a large, population-based cohort to re-examine this issue, applying a delayed entry methodology to avoid survival bias. Of 32,238 eligible patients diagnosed between 1995 and 2008, 29,908 (93%) had a single invasive melanoma, 2,075 (6%) had two and 255 (1%) had three. Allowing for differences in entry time, 10-year cause-specific survival for these three groups was 89% (95% CI = 88%-90%), 83% (95% CI = 80%-86%) and 67% (95% CI = 54%-81%), respectively. After adjustment for key prognostic factors, the hazard ratio (HR) of death within 10 years from melanoma was two times higher for those with two melanomas (HR = 2.01, 95% CI = ; p<0.001) and nearly three times higher when three melanomas were diagnosed (HR = 2.91, 95% CI = ; p<0.001) compared to people with a single melanoma. Melanoma-specific mortality remained elevated after adjusting for maximum thickness or ulceration of any melanoma regardless of the index tumor. After appropriately accounting for the interval between diagnosis of the first and subsequent melanomas, patients with multiple invasive melanomas have significantly poorer survival than patients with a single invasive melanoma. 2 P a g e
4 Introduction Steady increases in the incidence of melanoma over past decades have been well documented in North America, Europe, Australia and New Zealand (Erdmann et al., 2013; Nikolaou and Stratigos, 2014). Due to current high survival rates for melanoma overall (DeSantis et al., 2014; Nikolaou and Stratigos, 2014) combined with a large risk of developing a subsequent primary melanoma (Spanogle et al., 2010; Youlden et al., 2014), growing numbers of patients are consequently being diagnosed with more than one primary invasive cutaneous melanoma during their lifetime. Different studies have estimated that the chance of multiple primary melanomas occurring ranges from less than 1% to more than 10% of patients (Moore et al., 2015); we recently reported that 8% of patients in Queensland with a first primary invasive melanoma were diagnosed with a second primary invasive melanoma (Youlden et al., 2014). Despite the scale of the problem of multiple primary melanomas, there is little understanding about how multiplicity affects survival compared to a single primary melanoma. This is largely because of the methodological challenges involved. In most previous studies, survival after multiple melanoma has usually been measured from the time of first diagnosis (Bower et al., 2010; Burden et al., 1994; Doubrovsky and Menzies, 2003; Moseley et al., 1979; Murali et al., 2012; Savoia et al., 2012; Scheibner et al., 1982; Slingluff et al., 1993); however, this method produces results that are biased towards improved survival for multiple melanomas (known as survival bias ), as patients who live longer have greater opportunity to be diagnosed with additional melanomas (Bower et al., 2010; Doubrovsky and Menzies, 2003; Moseley et al., 1979). An alternate approach (Kricker et al., 2013; Rowe et al., 2015) has been to measure survival time from the diagnosis date of the most recent of the multiple primary melanomas, but 3 P a g e
5 this technique then biases outcome in the opposite direction due to disregarding the survival time between the first and last melanomas. Here we examine melanoma-specific survival following multiple primary invasive melanomas in a large, population-based cohort. In order to overcome the limitations of previous studies, we have utilised a methodology that appropriately incorporates the total period between diagnosis of the first and subsequent melanomas, without introducing a survival bias. Results Study cohort A total of 32,861 individuals were diagnosed with a first primary invasive melanoma in Queensland between 1995 and Of these, 488 were excluded on the basis of being younger than 15 or older than 89 at the time of diagnosis, 49 were omitted due to coding issues such as the date of death being the same as the date of diagnosis or the basis of diagnosis being either autopsy or death certificate only, and a further 86 were ineligible due to four or more primary invasive melanoma being diagnosed within 10 years of the first melanoma, leaving 32,238 patients (98%) in the study cohort. The majority (n=29,908, 93%) of eligible patients were diagnosed with a single primary invasive melanoma, 2,075 (6%) had two primary invasive melanomas and 255 (1%) were diagnosed with three primary invasive melanomas within 10 years of the index melanoma. For patients with two melanomas, 164 (8%) were synchronous, whereas five patients (2%) with three melanomas had them all diagnosed on the same day. Median follow-up across the entire cohort was 9.3 years. 4 P a g e
6 Overall, 9% of patients died from melanoma within 10 years of the first diagnosis (Table 1), but the proportion of melanoma-specific deaths was higher (13%) when three melanomas were recorded (p=0.04). Those with multiple melanomas tended to be older at first diagnosis (p<0.001), with a median age of 65 years for the group with three melanomas compared to 57 years for those with a single melanoma, although this age disparity was more apparent for males (67 and 59 years old, respectively) than for females (55 and 53 years old, respectively). Males outnumbered females in the cohort, with the proportion of males increasing from 57% for a single melanoma to 84% among patients with three invasive melanomas. Melanoma tumor characteristics Characteristics of the first melanoma varied significantly according to the number of melanomas diagnosed (Table 1). The first melanoma for patients with three primary invasive melanomas was more likely to occur on the trunk (40% versus 35% for patients with a single melanoma; p<0.001 for body site), have nodular morphology (11% versus 8%; p=0.011), be at least 2mm thick at diagnosis (16% versus 11%; p<0.001), and have reported ulceration (14% versus 9%; p=0.002). When the features of the second and third invasive melanomas were compared to the first melanoma for patients who had multiple melanomas (Table 2), no significant differences in regard to the distributions of body site, morphology, thickness category or ulceration were found. Survival Using the delayed entry method, unadjusted 10-year cause-specific survival (corrected for entry time only) was highest (89%) for patients with a single primary invasive melanoma, intermediate 5 P a g e
7 (83%) for those with two melanomas and lowest (67%) in patients who had three primary melanomas diagnosed within 10 years (Table 3 and Figure 2a). After adjusting for the characteristics of the index melanoma (Figure 2b), survival point estimates in patients with three melanomas were closer to other categories (79% versus 89% for one melanoma and 84% for two melanomas) essentially reflecting the poor prognosis attributes of the first melanoma in this group of patients. Even so, these differences were highly significant, with the likelihood of death from melanoma within 10 years of first diagnosis being twice as high for individuals with two melanomas (HR = 2.01, 95% CI = ; p<0.001) and nearly three times higher when three melanomas were recorded (HR = 2.91, 95% CI = ; p<0.001). Although the survival advantage for patients with a single melanoma was further attenuated when the thickness category and ulceration of the first melanoma were replaced in the multivariate model by the maximum thickness category and positive ulceration status of the second or third melanomas, variation in the estimates remained significant (Table 3 and Figure 2c). When the analysis was repeated using other definitions for survival time, no significant differences in outcome could be observed according to the number of melanomas diagnosed (p = for overall effect) when survival time was accrued from the date of diagnosis for the first invasive melanoma (Supplementary Table 1). Alternatively, compared to those with a single invasive melanoma, survival was significantly poorer for patients with either two (HR = 2.35, 95% CI = ; p<0.001) or three invasive melanomas (HR = 3.51, 95% CI = ; p<0.001) in the situation where survival time commenced from the date of last primary invasive melanoma diagnosis. 6 P a g e
8 Discussion Uncertainty currently surrounds the long-term survival of patients with multiple compared with single primary cutaneous melanomas. We used a population-based cohort to compare melanomaspecific survival in groups of patients with one, two or three primary invasive tumors over a 10 year follow-up period. Our results clearly demonstrate that, after making appropriate allowances for the time to diagnosis between first and subsequent melanomas by adopting a delayed entry analysis, survival from the time of first diagnosis of melanoma was significantly poorer for patients diagnosed with multiple primary invasive melanomas compared to a single primary invasive melanoma. The American Joint Committee on Cancer has adopted a pragmatic approach regarding prognostic criteria for patients with more than one melanoma, with their guidelines focusing solely on the most severe tumor (Balch et al., 2009). Our analysis reveals that the number of melanomas diagnosed also needs to be considered. Taking into account thickness and ulceration (as AJCC criteria) from either the first or most severe melanoma but also age, sex, morphology and body site, we were able to show that multiple melanomas have a major influence on patient survival even after adjusting for these key demographic and clinicopathological criteria. Our findings differ markedly from most previous studies on this topic, which have reported that being diagnosed with multiple melanomas has a protective influence (Bower et al., 2010; Burden et al., 1994; Doubrovsky and Menzies, 2003; Moseley et al., 1979; Murali et al., 2012; Savoia et al., 2012; Scheibner et al., 1982). However, in each of these studies, survival was analysed from the time of diagnosis of the first melanoma. It is therefore probable that the perceived 7 P a g e
9 improvement in survival for patients with two or more melanomas was attributable to survival bias, given that the longer a patient survives, the more likely they are to be diagnosed with additional melanomas (Bower et al., 2010; Doubrovsky and Menzies, 2003; Moseley et al., 1979). Two other studies found little difference in survival for people with single or multiple melanomas (Kricker et al., 2013; Slingluff et al., 1993), while Rowe and colleagues (Rowe et al., 2015) recently reported that multiple invasive melanomas were associated with poorer survival when measured from the date of diagnosis of the last melanoma. The outcome was not statistically significant, however, when survival was assessed from the time of diagnosis of the first invasive melanoma (Rowe et al., 2015). The authors acknowledged that choosing the last melanoma as the index for survival interval calculation biased the study towards poorer survival in those with multiple melanomas (Rowe et al., 2015). The use of the delayed entry method is therefore the most appropriate technique to compare survival between patients with a single invasive melanoma versus those with multiple invasive melanomas as it avoids the inherent biases associated with simply measuring survival time from either the first or last diagnosis. Delayed entry is commonly used in studies on survival (Campbell et al., 2015; Li et al., 2013) or the occurrence of second cancers (Brewster et al., 2004) to account for the lag between initial cancer diagnosis and study enrolment. These situations are analogous to the present investigation, in that patients with multiple melanomas can be considered to have been enrolled (included) in our study from the date of diagnosis of either their second or third melanoma. 8 P a g e
10 When we replicated our study based on follow-up from the time of diagnosis of the first melanoma, the number of invasive melanomas diagnosed had no bearing on survival in accordance with some previous reports (Kricker et al., 2013; Slingluff et al., 1993). Similarly as previously reported by us or others, multiple invasive melanomas were a hazard if survival time was accumulated from the date of diagnosis of the last melanoma (Rowe et al., 2015). Therefore, the population cohort studied here allows replication of previous reports on survival of multiple melanomas. Only the delayed entry method allows avoiding the biases inherent to both of these other models while still pointing to a survival disadvantage for patients with multiple invasive melanomas. Unlike the recent study by Kricker and colleagues (Kricker et al., 2013) we considered invasive melanomas only, having previously demonstrated that diagnosis of an additional in situ melanoma is inconsequential in terms of influencing the prognosis for patients with an invasive melanoma (Youlden et al., 2016). Counting in situ lesions as contributing to melanoma multiplicity for the purposes of survival estimation thus has the potential to dilute any survival disparities towards the null. This may then explain the lack of difference in outcome reported by Kricker et. al. (Kricker et al., 2013), despite the fact that they attempted to overcome the bias towards improved survival for multiple melanomas by measuring survival time from the tumor that was diagnosed last. In our analysis, attributes of second and third melanomas did not markedly differ from the first tumor for patients with multiple melanomas. Interestingly, however, characteristics of the first 9 P a g e
11 invasive melanoma differed among patients with subsequent invasive melanomas compared with those who had a single invasive melanoma only. In particular, for patients with multiple invasive melanomas, initial tumors were thicker and more likely to be ulcerated or nodular, all being associated with poorer outcome (Baade et al., 2015). These differences being already present at the first invasive melanoma may point to a propensity in these patients to develop more aggressive disease, adding further support to our findings. Indeed, melanoma survival has been suspected to have an inherited component as reflected by familial clustering of fatal melanomas (Brandt et al., 2011). The older age at first diagnosis for those with multiple melanomas may also account for at least some of the differences in the characteristics of the initial invasive lesion; for instance, older people are more likely to present with nodular or ulcerated melanomas (Lasithiotakis et al., 2010). A possible alternative would however be that patients with multiple melanomas do not have the required awareness of their melanoma risk and delay surveillance and treatment. Besides our use of the delayed entry method to counter the biases present in earlier studies on survival for multiple melanomas, another advantage of this study over previous studies was the much larger cohort size, giving us added power to detect differences in survival. In terms of limitations, the precision of cause of death coding is subject to some uncertainty, particularly for older patients when several possible causes may coincide. Information from hospital records, death certificates, autopsy reports and pathology records was used by the Queensland Cancer Registry to ensure that cause of death was assigned as accurately as possible. A further limitation was that information on other clinical indicators, such as sentinel node status, was unavailable from routinely collected registry data, and so we could not adjust the results for these 10 P a g e
12 additional prognostic variables. Similarly, information on family history of melanoma was not available. Given increasing melanoma incidence and prolonged survival for most patients, it is vital that reliable prognostic information is available for patients with multiple invasive lesions and for their clinicians. Contrary to existing evidence, our findings overwhelmingly point towards poorer outcomes in patients with multiple invasive melanomas. This in turn emphasises the need for adequate recording of past disease in melanoma patients. Knowledge of a patient s history of multiple melanomas should prompt careful surveillance to detect new or recurrent disease. Materials and Methods Data De-identified records for cases of invasive melanoma (ICD-O-3 code C44 and morphology M872-M879) diagnosed between 1995 and 2013 were obtained from the Queensland Cancer Registry in accordance with ethics guidelines and approvals. The Queensland Cancer Registry is a population-based collection with virtually complete ascertainment of all diagnoses within the state of Queensland in Australia. Notification of all cancer diagnoses is required by law, apart from basal and squamous cell carcinomas of the skin (Queensland Cancer Registry and Cancer Council Queensland, 2014). Variables in the data extract included sex, age at diagnosis, tumor behaviour, body site, morphology, Breslow thickness, ulceration, date of diagnosis and date and cause of death (where applicable). Mortality status as at 31 December 2013 was ascertained by linkage with the Queensland Registry of Births, Deaths and Marriages and the National Death Index of Australia. 11 P a g e
13 The study cohort comprised all Queensland residents aged years who were diagnosed with a first primary invasive melanoma between 1995 and 2008, thus allowing a minimum follow-up of five years. Where relevant, records for second and third primary invasive melanomas that occurred within 10 years of the index melanoma were connected through unique patient numbers. Subsequent primary melanomas which were diagnosed more than ten years after the first diagnosis were not considered. In situ melanomas (Youlden et al., 2016) and recurrent or cutaneous metastases based on pathology findings were also disregarded. Patients were excluded from the cohort if they were diagnosed with four or more primary invasive melanomas within ten years, when the date of diagnosis was the same as the date of death, or where the basis of diagnosis was either autopsy or death certificate only. Analysis The cohort was stratified according to the number of invasive primary melanomas diagnosed (up to a maximum of three). If two or more melanomas were diagnosed on the same day, the order was determined according to the sequence in which they were registered. Key demographic and clinical characteristics for the first primary invasive melanoma were compared across these three strata using chi-squared tests for categorical variables and nonparametric k-sample tests for the equality of median values. For persons with multiple melanomas, the features of the first melanoma were also compared with the corresponding characteristics of the second and third melanomas, with differences in the distribution for categorical variables evaluated by estimating variance based on Taylor linearization to account for clustering. 12 P a g e
14 Cause-specific survival time accumulated from the date of diagnosis of the first primary invasive melanoma to either the date of death, the end of the study period (31 December 2013) or ten years from the date of initial diagnosis, whichever occurred first. Censoring was applied if patients remained alive at the end of the follow-up period, or if they died and the cause of death was not coded as melanoma. Delayed entry (also known as left truncation) (Cleaves MA et al., 2008) was used to counter the inherent bias towards longer survival times among those diagnosed with a subsequent melanoma. For people with a single melanoma, the survival time is measured from the date of diagnosis of that index melanoma. Typically, most previous studies have used this same approach when considering people with two or more melanomas, that is, calculating the survival time from the date the index melanoma was diagnosed and using all that time in the analysis (Group A in Figure 1). Other studies have started the survival time from when the last melanoma was diagnosed (Group B in Figure 1). However, under the delayed entry approach, while the survival time for patients with multiple melanomas starts at the date of diagnosis of the index melanoma, this time only contributes to the analysis from the time when their last melanoma (second or third) was diagnosed (Group C in Figure 1), and is not reset to zero, as would occur if the subsequent melanoma were used as the index rather than the initial melanoma (Kricker et al., 2013; Rowe et al., 2015). For example, if an individual was diagnosed with two melanomas three years apart, their survival time would only contribute to the calculations from the third year onwards. Similarly, if a third melanoma was diagnosed five years after the first, then survival 13 P a g e
15 time would only accrue from the fifth year, ignoring the date of diagnosis of the second melanoma. Unadjusted 10-year survival was calculated using the Kaplan-Meier method. Flexible parametric survival models (Royston and Lambert, 2011) were then applied to the data. The baseline survival distribution is represented as a restricted cubic spline function in flexible parametric survival models, allowing non-proportional effects in the underlying hazard function to be estimated more readily compared to the simpler linear function in traditional Cox proportional hazard models. After assessing various options for the scale parameter and the number of internal knots for the cubic spline function according to the Bayes information criterion statistic, the model providing the best fit was on the normal scale with three internal knot points. The multivariate models were adjusted for sex, age at diagnosis, body site, melanoma morphology, thickness category and ulceration, with body site and thickness included as time varying variables. Melanoma thickness was fitted in the flexible parametric survival models as a categorical rather than a continuous variable allowing more stable estimates with minimal effects on the model outcomes (comparative results not shown). Two models were fitted; the first model was based solely on the characteristics of the first primary melanoma, while the second model applied the characteristics of the melanoma at highest risk of recurrence in terms of thickness category and ulceration for patients who were diagnosed with multiple melanomas. Given that delayed entry was only applied to patients with multiple invasive melanomas, we could not assume independence between the entry and failure 14 P a g e
16 events, and so entry time was also incorporated as a covariate in the models (including the unadjusted results) in order to avoid the possibility of introducing late entry bias (Matsuura and Eguchi, 2005). Results were expressed in terms of excess hazard ratios (HRs) along with corresponding 95% confidence intervals (95% CIs). Finally, to allow comparison of different methods of estimation of the survival interval, our model (first model) using delayed entry (Figure 1, Group C) was compared to two alternative definitions of survival i.e. including all follow-up time from the date of diagnosis of the first melanoma (Figure 1 Group A) and considering survival commencing from the date of diagnosis of the final melanoma only (Figure 1 Group B). All analyses were conducted using Stata/SE version 14.1 for Windows. The stpm2 command (Royston and Lambert, 2011) was used to fit the flexible parametric survival models. 15 P a g e
17 Conflict of Interest The authors state no conflict of interest. Acknowledgements The authors would like to acknowledge the staff working in the Queensland Cancer Registry who provided us with the data extract used in this analysis. Funding KK was supported by a National Health and Medical Research Council (NHMRC) Fellowship (# ), AG was supported by a NHMRC Program Grant (#552429), and Philippa Youl was funded by a NHMRC Early Career Fellowship (# ). 16 P a g e
18 References Baade PD, Royston P, Youl PH, Weinstock MA, Geller A, Aitken JF. Prognostic survival model for people diagnosed with invasive cutaneous melanoma. BMC Cancer 2015;15:27. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27: Bower MR, Scoggins CR, Martin RC, 2nd, Mays MP, Edwards MJ, Reintgen DS, et al. Second primary melanomas: incidence and outcome. Am Surg 2010;76: Brandt A, Sundquist J, Hemminki K. Risk of incident and fatal melanoma in individuals with a family history of incident or fatal melanoma or any cancer. Br J Dermatol 2011;165: Brewster AM, Alberg AJ, Strickland PT, Hoffman SC, Helzlsouer K. XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004;13: Burden AD, Vestey JP, Sirel JM, Aitchison TC, Hunter JA, MacKie RM. Multiple primary melanoma: risk factors and prognostic implications. BMJ 1994;309(6951):375. Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev 2015;24: Cleaves MA, Gould WW, Gutierrez RG, Marchenko YU. An Introduction to Survival Analysis using Stata (second edition). College Station TX: Stata Press; DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, CA Cancer J Clin 2014;64: Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol 2003;139: Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma are recent generations at higher or lower risk? Int J Cancer 2013;132: Kricker A, Armstrong BK, Goumas C, Thomas NE, From L, Busam K, et al. Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol 2013;149: P a g e
19 Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 2010;20: Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 2013;31: Matsuura M, Eguchi S. Modeling late entry bias in survival analysis. Biometrics 2005;61: Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM. Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to J Am Acad Dermatol 2015;73: Moseley HS, Giuliano AE, Storm FK, 3rd, Clark WH, Robinson DS, Morton DL. Multiple primary melanoma. Cancer 1979;43: Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, et al. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer 2012;118: Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014;170:11-9. Queensland Cancer Registry, Cancer Council Queensland. Cancer in Queensland 1982 to 2012: Incidence, mortality, survival and prevalence. Brisbane: Cancer Council Queensland, Rowe CJ, Law MH, Palmer JM, MacGregor S, Hayward NK, Khosrotehrani K. Survival outcomes in patients with multiple primary melanomas. J Eur Acad Dermatol Venereol 2015;29: Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. College Station, Texas: Stata Press; Savoia P, Osella-Abate S, Deboli T, Marenco F, Stroppiana E, Novelli M, et al. Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year singleinstitution study. J Eur Acad Dermatol Venereol 2012;26: Scheibner A, Milton GW, McCarthy WH, Norlund JJ, Pearson LJ. Multiple primary melanoma - a review of 90 cases. Australas J Dermatol 1982;23: P a g e
20 Slingluff CL, Jr., Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 1993;113: Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010;62: Youlden DR, Khosrotehrani K, Green AC, Soyer HP, Youl PH, Kimlin MK, et al. Diagnosis of an additional in situ melanoma does not influence survival for patients with a single invasive melanoma: a registry-based follow-up study. Australas J Dermatol 2016;57: Youlden DR, Youl PH, Soyer HP, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, JAMA Dermatol 2014;150: P a g e
21 Table 1: Cohort characteristics of first primary invasive melanomas 1 by presence of additional primary invasive melanomas, Queensland, Patients with a single primary invasive melanoma Patients with two primary invasive melanomas Patients with three or more primary invasive melanomas Characteristics of first primary invasive melanoma p Eligible patients (n) 29,908 2, Median follow-up (years) <0.001 Median age at diagnosis (years) <0.001 Col % Col % Col % Mortality status 10 years after diagnosis Alive Melanoma-specific death Non-melanoma death Sex 3 <0.001 Males Females Body site 3 <0.001 Head and neck Trunk Upper limbs and shoulders Lower limbs Not specified Morphology Nodular melanoma Melanoma in naevus Lentigo maligna melanoma Superficial spreading melanoma Other specified melanoma Not otherwise specified Thickness 3 <0.001 < 1mm mm to < 2mm >= 2mm Not recorded Ulceration No Yes Not recorded Notes: 1. Characteristics shown are for first primary melanoma only. 2. First primary invasive melanomas were diagnosed between 1995 and 2008, with follow-up to 31 Dec 2013 for diagnosis of subsequent primary invasive melanomas (maximum of 10 years of follow-up from the date of diagnosis of the first primary invasive melanoma). 3. P-values based on chi-squared tests for categorical variables and nonparametric k-sample tests for medians. 20 P a g e
22 Table 2: Characteristics of second and third primary invasive melanomas compared to corresponding first primary invasive melanoma, Queensland, First primary invasive melanoma Second primary invasive melanoma First primary invasive melanoma Third primary invasive melanoma Eligible patients (n) 2, Median time from diagnosis of first primary melanoma (years) n.a. 3.1 n.a. 5.1 Median age at diagnosis (years) Col % Col % Body site 2 Head and neck Trunk Upper limbs and shoulders Lower limbs Not specified p = p = Morphology 2 Nodular melanoma Melanoma in junctional naevus Lentigo maligna melanoma Superficial spreading melanoma Other specified melanoma Not otherwise specified p = p = Thickness 2 < 1mm mm to < 2mm >= 2mm Not recorded p = p = Ulceration 2 No Yes Not recorded p = p = Notes: 1. Includes second and third primary invasive melanomas which were diagnosed within 10 years from the date of diagnosis of the first primary invasive melanoma. 2. P-values based on chi-squared statistic which was converted into an F statistic after correcting for clustering of melanomas by patients. Test statistics exclude the category not specified or not recorded. 21 P a g e
23 Table 3: Ten year adjusted cause-specific survival estimates and hazard ratios by number of primary invasive melanomas, Queensland, Number of primary invasive melanomas n Ten-year cause-specific survival estimates 2 (95% CI) Unadjusted Model 3 Excess hazard ratios (95% CI) p Single 29, ( ) 1.00 Two 2, ( ) 1.49 ( ) < Three ( ) 2.69 ( ) < Overall effect: p < Adjusted Results Model 1 4 Single 29, ( ) 1.00 Two 2, ( ) 2.01 ( ) < Three ( ) 2.91 ( ) < Overall effect: p < Adjusted Results Model 2 5 Single 29, ( ) 1.00 Two 2, ( ) 1.49 ( ) Three ( ) 2.08 ( ) Overall effect: p = Notes: 1. First primary invasive melanomas were diagnosed between 1995 and 2008, with follow-up to 31 Dec 2013 for diagnosis of subsequent primary invasive melanomas (maximum of 10 years of followup from the date of diagnosis of the first primary invasive melanoma). 2. Survival time was calculated from the date of diagnosis of the first primary invasive melanoma with delayed entry when subsequent melanomas were diagnosed. 3. Model is adjusted for entry time only. 4. Adjusted for entry time, sex and the following variables relating to the first primary invasive melanoma: age at diagnosis, body site, morphology, thickness category and ulceration. 5. Adjusted for entry time, sex, thickness category of the thickest melanoma, presence of ulceration in any melanoma and the following variables relating to the first primary invasive melanoma: age at diagnosis, body site, and morphology. 22 P a g e
24 Figure legends Figure 1: Comparison of methods used to measure survival time. Figure 2: Unadjusted and adjusted cause-specific survival for single and multiple primary invasive melanomas, Queensland, a) The survival curves were adjusted for entry time only. b) The survival curves were adjusted for entry time, sex and the following variables relating to the first primary invasive melanoma: age at diagnosis, body site, morphology, thickness category and ulceration. c) The survival curves were adjusted for entry time, sex, thickness category of the thickest melanoma, presence of ulceration in any melanoma and the following variables relating to the first primary invasive melanoma: age at diagnosis, body site, and morphology. 23 P a g e
25
26
1 Cancer Council Queensland, Brisbane, Queensland, Australia.
Title: Diagnosis of an additional in situ does not influence survival for patients with a single invasive : A registry-based follow-up study Authors: Danny R Youlden1, Kiarash Khosrotehrani2, Adele C Green3,4,
Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
THE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994 2004 Ann Richardson, Lynn Fletcher, Mary Jane
The first year counts: cancer survival among Indigenous and non-indigenous Queenslanders
The first year counts: cancer survival among Indigenous and non-indigenous Queenslanders 1997-2006 Author Cramb, Susanna M., Garvey, Gail, Valery, Patricia C., Williamson, John D., Baade, Peter D. Published
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
Talk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
Published in: Cancer Causes and Control. DOI: /s Link to publication in the UWA Research Repository
The incidence of second primary invasive melanoma in Queensland, 1982-2003 Mccaul, K. A., Fritschi, L., Baade, P., & Coory, M. (2008). The incidence of second primary invasive melanoma in Queensland, 1982-2003.
Johan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
Epidemiology DATA AND METHODS
British Journal of Cancer () 9, 91 9 All rights reserved 7 9/ $3. www.bjcancer.com Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
The first year counts: cancer survival among Indigenous and non-indigenous Queenslanders,
Western University Scholarship@Western Aboriginal Policy Research Consortium International (APRCi) 3-5-2012 The first year counts: cancer survival among Indigenous and non-indigenous Queenslanders, 1997
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe
Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)
Incidence rates of cutaneous malignant melanoma. ActaDV ActaDV. Multiple Primary Melanomas: A Common Occurrence in Western Sweden
CLINICAL REPORT Multiple Primary Melanomas: A Common Occurrence in Western Sweden Magdalena CLAESON 1, Paul HOLMSTRÖM 2, Stefan HALLBERG 2, Martin GILLSTEDT 1, Helena GONZALEZ 1, Ann-Marie WENNBERG 1 and
ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
Report on Cancer Statistics in Alberta. Melanoma of the Skin
Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of
1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
ARTICLE. Epidemiology of melanoma in situ in New Zealand: Sam Rice, Lifeng Zhou, Richard Martin ABSTRACT
Epidemiology of melanoma in situ in New Zealand: 2008 2012 Sam Rice, Lifeng Zhou, Richard Martin ABSTRACT AIM: The incidence of melanoma in situ varies throughout the world. It is associated with excellent
Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
Cancer survival and prevalence in Tasmania
Cancer survival and prevalence in Tasmania 1978-2008 Cancer survival and prevalence in Tasmania 1978-2008 Tasmanian Cancer Registry University of Tasmania Menzies Research Institute Tasmania 17 Liverpool
Melanoma Thickness Trends in the United States,
ORIGINAL ARTICLE in the United States, 26 Vincent D. Criscione 1,2 and Martin A. Weinstock 1,2 Over the past two decades, numerous efforts have been initiated to improve screening and early detection of
NIH Public Access Author Manuscript Arch Dermatol. Author manuscript; available in PMC 2009 August 20.
NIH Public Access Author Manuscript Published in final edited form as: Arch Dermatol. 2009 August ; 145(8): 879 882. doi:10.1001/archdermatol.2009.176. Antioxidant Supplementation and Risk of Incident
Report on Cancer Statistics in Alberta. Kidney Cancer
Report on Cancer Statistics in Alberta Kidney Cancer November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the Report
Amelanotic melanoma of the skin detailed review of the problem
of the skin detailed review of the problem Strahil Strashilov 1, Veselin Kirov 2, Angel Yordanov 3, Yoana Simeonova 4 and Miroslava Mihailova 5 1. Department of Plastic Restorative, Reconstructive and
Childhood Cancer Survivor Study Analysis Concept Proposal
Title: Multiple Subsequent Neoplasms Working Group and Investigators: Childhood Cancer Survivor Study Analysis Concept Proposal This proposed publication will be within the Second Malignancy Working Group
Extent of lymphadenectomy for esophageal squamous cell cancer: interpreting the post-hoc analysis of a randomized trial
Accepted Manuscript Extent of lymphadenectomy for esophageal squamous cell cancer: interpreting the post-hoc analysis of a randomized trial Vaibhav Gupta, MD PII: S0022-5223(18)33169-6 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.055
Report on Cancer Statistics in Alberta. Breast Cancer
Report on Cancer Statistics in Alberta Breast Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment Makenzie L. Hawkins, MSPH 1 Matthew J. Rioth, MD 1,2 Megan M. Eguchi, MPH 1 Myles Cockburn, Phd
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience
2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje
Rebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas
Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas Marius Rademaker BM, FRCP(Edin), FRACP, DM; Amanda Oakley MBChB, FRACP, DipHealInf Dermatology Department,
RESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry
DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko
Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
Survival of Indigenous and non-indigenous Queenslanders after a diagnosis of lung cancer: a matched cohort study
Survival of and non- Queenslanders after a diagnosis of lung cancer: a matched cohort study Michael D Coory, Adele C Green, Janelle Stirling and Patricia C Valery Lung cancer is the commonest cancer among
The Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
Accepted Manuscript. Reply to: Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study
Accepted Manuscript Reply to: Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study Matthew D. Mansh, MD, Dustin H. Marks, BS PII: S0190-9622(18)32503-9 DOI: 10.1016/j.jaad.2018.07.067
Citation for published version (APA): Huismans, A. (2015). Regional aspects of melanoma diagnosis and treatment [S.l.]: [S.n.]
University of Groningen Regional aspects of melanoma diagnosis and treatment Huismans, Annemarleen IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population-Based Matched Cohort Study
American Journal of Transplantation 2014; 14: 1368 1375 Wiley Periodicals Inc. C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12716
Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD
Accepted Manuscript Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD PII: S0022-5223(18)33135-0 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.036
Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
Associated Detection Patterns, Lesion Characteristics, and Patient Characteristics
1562 Thin Primary Cutaneous Melanomas Associated Detection Patterns, Lesion Characteristics, and Patient Characteristics Jennifer L. Schwartz, M.D. 1 Timothy S. Wang, M.D. 1 Ted A. Hamilton, M.S. 1 Lori
Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women
Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women Liljana Mervic 1,2 * 1 Department of Dermatology, Center of Dermatooncology, University of Tüebingen, Germany, 2
The Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.
National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of
Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
Chapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
Racial differences in six major subtypes of melanoma: descriptive epidemiology
Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge
Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
12. Malignant Melanoma of Skin
KEY FACTS 12. Malignant Melanoma of Skin ICD-9 172 On average 160 melanomas of the skin were registered per year. Twice as common in females than in males. Higher than expected numbers in Southern Board
Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists
Accepted Manuscript Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists Shearwood McClelland, III, MD, Kiri
Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
MEASURING CANCER CURE IN IRELAND
MEASURING CANCER CURE IN IRELAND 2019 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) IARC International Agency for Research
Professor Peter Soyer. Academic Dermatologist Brisbane, Australia
Professor Peter Soyer Academic Dermatologist Brisbane, Australia What s New in Melanoma Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute &
Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis
538 Ivyspring International Publisher Research Paper Journal of Cancer 2011; 2: 538-543 Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis James B. Macdonald 1, Amylou C.
Changes in the site distribution of common melanoma subtypes in Queensland, Australia over time: implications for public health campaigns
Changes in the site distribution of common melanoma subtypes in Queensland, Australia over time: implications for public health campaigns Author Youl, Philippa, Youlden, D., Baade, Peter Published 2013
Melanoma incidence and mortality in Scotland
British Journal of Cancer (7) 9, 177 1777 All rights reserved 7 9/7 $3. www.bjcancer.com Melanoma incidence and mortality in Scotland 1979 3 RM MacKie,1, C Bray, J Vestey 3, V Doherty, A Evans 5, D Thomson
Surgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
PAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
Introduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
Updates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
CURRENT ISSUES IN TRANSPLANT DERMATOLOGY
CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this
STUDY. Analysis of the Melanoma Epidemic, Both Apparent and Real
Analysis of the Melanoma Epidemic, Both Apparent and Real Data From the 1973 Through 1994 Surveillance, Epidemiology, and End Results Program Registry Leslie K. Dennis, PhD STUDY Background: The incidence
JAM ACAD DERMATOL VOLUME 76, NUMBER 2. Research Letters 351
JAM ACAD DERMATOL Research Letters 351 Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes To the Editor:
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
Title Page. Title: Clinical whole-body skin examination reduces the incidence of thick melanomas.
Page 1 of 34 Title Page Title: Clinical whole-body skin examination reduces the incidence of thick melanomas. Authors: Joanne F. Aitken, BSc Hons, SM Epid, PhD 1. Director of Cancer Registries and Consultant
The effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
Cancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)
1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.
Author s Accepted Manuscript
Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.
Accepted Manuscript. Early stage (ct2n0) esophageal cancer: should induction therapy be a standard? Michael Lanuti, MD
Accepted Manuscript Early stage (ct2n0) esophageal cancer: should induction therapy be a standard? Michael Lanuti, MD PII: S0022-5223(18)30392-1 DOI: 10.1016/j.jtcvs.2018.02.029 Reference: YMTC 12608 To
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
Does the lung nodule look aggressive enough to warrant a more extensive operation?
Accepted Manuscript Does the lung nodule look aggressive enough to warrant a more extensive operation? Michael Kuan-Yew Hsin, MBChB, MA, FRCS(CTh), David Chi-Leung Lam, MD, PhD, FRCP (Edin, Glasg & Lond)
Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
Bioprosthetic aortic valve replacement: a high standard of comparison for transcatheter aortic valve implantation
Accepted Manuscript Bioprosthetic aortic valve replacement: a high standard of comparison for transcatheter aortic valve implantation Aaron Martin, MD, Michael H. Yamashita, MDCM, MPH PII: S0022-5223(18)32910-6
Analysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
University of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis
DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis Temeida Alendar 1, Harald Kittler
The Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Chronic type A dissection: when to operate? Francois Dagenais, MD PII: S0022-5223(18)33131-3 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.032 Reference: YMTC 13781 To appear in: The
Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival
An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert
Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol
Krishnan et al. BMC Cancer (2017) 17:859 DOI 10.1186/s12885-017-3871-7 RESEARCH ARTICLE Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol study Open Access Kavitha
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
Landmarking, immortal time bias and. Dynamic prediction
Landmarking and immortal time bias Landmarking and dynamic prediction Discussion Landmarking, immortal time bias and dynamic prediction Department of Medical Statistics and Bioinformatics Leiden University
Template 1 for summarising studies addressing prognostic questions
Template 1 for summarising studies addressing prognostic questions Instructions to fill the table: When no element can be added under one or more heading, include the mention: O Not applicable when an
Comment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis
Accepted Manuscript Comment on Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis Maglie Roberto, MD, Antiga Emiliano, MD, PhD, Caproni Marzia, MD, PhD PII: S0190-9622(17)32812-8
This is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper:
This is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/127789/ Version: Accepted Version Article: Muinonen-Martin,
Laboratory for Quantitative Medicine Technical Report #2 April 10, Equation Parameters
Laboratory for Quantitative Medicine Technical Report #2 April 10, 2009 Equation Parameters This report summarizes all the equation parameters used by the web-based calculators, and provides information
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
Thomas Jefferson University Jefferson Digital Commons Department of Surgery Faculty Papers Department of Surgery 1-1-2012 Lymph node ratio is an important and independent prognostic factor for patients
The New England Journal of Medicine A POPULATION-BASED STUDY OF SEIZURES AFTER TRAUMATIC BRAIN INJURIES
A POPULATION-BASED STUDY OF SEIZURES AFTER TRAUMATIC BRAIN INJURIES JOHN F. ANNEGERS, PH.D., W. ALLEN HAUSER, M.D., SHARON P. COAN, M.S., AND WALTER A. ROCCA, M.D., M.P.H. ABSTRACT Background The risk